Basel, October 22, 2026

Roche confirmed its outlook for 2026 in Basel on October 22, 2026, after the group generated 7 percent more revenue in the third quarter at constant exchange rates.

The Swiss pharmaceutical group Roche has confirmed its annual outlook. For the current year, the group expects mid-single-digit revenue growth at constant exchange rates, as well as high-single-digit growth in adjusted earnings per share.

Roche also intends to increase its dividend in Swiss francs once again. This maintains the group's outlook for a further increase in shareholder remuneration.

Growth in the third quarter